Matches 101 - 150 out of 169 < 1 2 3 4 >
Match Document Document Title
6297355 Polypeptides displaying HBV antigenicity or hbv antigen specificity  
Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying HBV antigenicity and genes coding therefor and methods of making and using these molecules, hosts,...
6284249 Fusion polypeptide having the C protein and E1 protein of hepatitis C virus  
The invention concerns a pharmaceutical composition for treating or preventing C hepatitis (HCV), induced infections, which in a preferred embodiment, comprises a main active principle, (i) a...
6280734 Simian-human HAV having a chimeric 2C protein  
The present invention discloses simian-human hepatitis A virus chimeric genomes which encode a hepatitis A virus having a chimeric 2C protein. The invention further discloses the use of these...
6270955 Pharmaceutical compositions and methods for producing antibodies to hepatitis b virus and kits and methods for detecting antibodies to hepatitis b virus  
Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying HBV anti-genicity and genes coding therefor and methods of making and using these molecules, hosts,...
6268122 Recombinant DNA molecules and their method of production  
Recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying HBV antigenicity and genes coding therefor and methods of making and using these molecules, hosts,...
6251654 Modified small RNA viruses  
Small RNA viruses and virus-like particles (VLPs) have altered or substituted Ig-like domains so as to modify host cell tropism. The invention also relates to the use of such small RNA viruses and...
6235284 Synthetic polypeptides belonging to the hepatitis C virus (HCV) and which can be used especially for detecting the latter  
The invention relates to a polypeptide comprising a peptide sequence belonging to the sequence of the first 62 amino acids of the terminal part of the CORE (or capsid) protein of the human...
6231864 Strategically modified hepatitis B core proteins and their derivatives  
A strategically modified hepatitis B core protein is described, where an insert is provided, preferably in an immunodominant region of the nucleocapsid protein, containing a chemically reactive...
6225458 Process for the production of DNA comprising the genome of the hepatitis B virus and vector including it  
The invention relates to a process for producing DNA corresponding to that of the DNA of the virus of B hepatitis. It comprises cloning in bacteria the latter DNA, previously repaired by means of...
6221664 Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method  
This invention is a vaccine prepared from antigen-antibody-recombinant plasmid DNA complex. This invention is a complex vaccine composed of at least one microbial source antigen and its (their)...
6217872 Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide  
Disclosed is an isolated non-A, non-B hepatitis virus genomic CDNA covering the entire region of the virus gene nucleotide sequence from the 1st to 9416th nucleotides shown in FIG. 2(1) through...
6210675 PT-NANB hepatitis polypeptides  
The invention relates to post-transfusional non-A non-B hepatitis viral polypeptide, DNA sequences encoding such viral polypeptide, expression vectors containing such DNA sequences, and hosts...
6210901 Specific binding substances for antibodies and their use for immunoassays or vaccines  
The invention relates to derivatives of hepatitis C virus amino acid sequences. These derivatives can be used to screen samples, such as blood, to determine if antibodies to hepatitis C virus are...
6165730 Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays  
The etiological agent responsible for non-A, non-B hepatitis has been identified and termed hepatitis C virus (HCV). The HCV genome is a linear, positive-stranded RNA molecule with a length of...
6153378 Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus  
The unprocessed polyprotein initially translated from the genome of a positive-stranded RNA virus contains epitopic configurations that are not retained in the processed proteins. The structural...
6146643 Human/simian chimeric hepatitis A virus vaccine  
The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian...
6143715 Hepatitis C inhibitor peptide analogues  
Compound of formula (I) active against the Hepatitis C virus: ##STR1## wherein B is an acyl derivative; a is 0 or 1; R 6 , when present, is carboxy(lower)alkyl; b is 0 or 1; R 5 , when present, is...
6136322 Hepatitis A virus deletion mutants and vaccine formulations containing the same  
Disclosed are live hepatitis A virus deletion mutants having a deletion mutation in the 5' nontranslated region of the viral genome. The deletion mutation may be selected from the group consisting...
6136319 Method of treating viral diseases in animals  
A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a...
6121020 Hepatitis C E1 and E2 polypeptides and methods of obtaining the same  
Novel Hepatitis C E1 and E2 truncated polypeptides and complexes comprising these polypeptides, are disclosed. The polypeptides are C-terminally truncated to remove all or a portion of their...
6099840 Hepatitis B vaccine  
A variant HBsAg protein of fragment thereof displaying the antigenicity of Hepatitis B virus surface antigen is disclosed, in which the variant protein or fragment thereof (vHBsAg) comprises a...
6090388 Peptide composition for prevention and treatment of HIV infection and immune disorders  
The invention provides peptides comprising a sequence homologous to a portion of the CDR-2 like domain of CD4, covalently linked to a helper T cell epitope, and optionally to other...
6051238 Stabilizers for lyophilized mumps vaccines  
Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric...
6025141 Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form  
6020167 Composition used as a therapeutic agent against chronic viral hepatic diseases  
6020122 Hepatitis C virus second envelope (HCV-E2) glycoprotein expression system  
This invention provides a novel mammalian expression system that is capable of generating high levels of expressed hepatitis C virus (HCV) proteins which have previously proved difficult to express...
6013264 Vaccine  
Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37° C. and is highly...
5980901 Viral defective interfering particles and uses thereof  
The present invention provides a composition of matter comprising a defective interfering virus particle, wherein said particle naturally occurs in a human infection and wherein said particles has...
5980899 Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells  
The cytotoxic T cell response to the protein encoded by the NS5 region of hepatitis C virus was determined using 28 peptides from NS5 which were selected by an amphipathicity algorithm as...
5968775 Hepatitis C virus infected cell systems  
The present invention is directed to extracorporeal cell systems infected with hepatitis C virus (HCV). The present invention also relates to products of such cell systems and their use as vaccines...
5932219 Hepatitis delta virus p27.sup.δ and p24.sup.δ vaccine  
The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate...
5919454 Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications  
This invention relates to human or murine monoclonal antibodies specific for a peptide sequence of HCV E1, fragments of said monoclonal antibodies, hybridomas producing said monoclonal antibodies,...
5885768 Hepatitis E virus peptide antigen and antibodies  
Immunogenic peptides derived from the ORF1, ORF2, and ORF3 regions of hepatitis E virus (HEV), diagnostic reagents containing the peptide antigens, vaccine compositions containing the antigens, and...
5856084 Hepatitis B vaccine  
A variant or so-called "escape mutant" HBsAg protein or fragment thereof displaying the antigenicity of hepatitis B virus surface antigen is disclosed, in which the mutant protein or fragment...
5843450 Hepatitis GB Virus synthetic peptides and uses thereof  
Hepatitis GB Virus (HGBV) synthetic peptides useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences and antibodies which...
5840305 Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity  
The present invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner...
5770689 Hepatitis E virus ORF Z peptides  
An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading...
5750350 Hepatitis δ diagnostics  
The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA Of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate...
5747044 Hepatitis delta diagnostics and vaccines  
The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate...
5731187 Process for preparing hepatitis A (HAV) antigens and vaccines  
Process for preparing hepatitis A (HAV) antigens and vaccines. The HAV virus is multiplied on competent cells, the infected cells are lysed, the supernatant is recovered and the purification is...
5693497 Process for expressing the hepatitis B virus antigen using a Saccharomyces cerevisiae transformant  
There is disclosed an antigen comprising an amino acid sequence of the suce antigen of a hepatitis B virus. The present antigen can be produced easily and safely at low cost by means of recombinant...
5674676 HCV peptide antigens and method of determining HCV  
New HCV peptide antigens are described. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the preparation of antibodies to HCV and as immunogens for the...
5670630 Expression of hepatitis B S and preS.sub.2 proteins in methylotrophic  
A process for the enhanced production of antigenic particles consisting essentially of hepatitis B S protein and preS 2 protein. Also disclosed are novel DNA molecules and hosts transformed with...
5667782 Multiple particulate antigen delivery system  
Antigens in particulate form are provided wherein chimeric antigens having foreign epitopes are presented on or within virus-like particles (VLPs) or virus core-like particles (CLPs). The VLPs and...
5662906 Non-a non-b hepatitis-specific antigen and its use in hepatitis diagnosis  
This invention relates to a DNA fragment comprising a base sequence encoding a non-A non-B hepatitis-specific antigen polypeptide, said base sequence being obtained using genetic engineering...
5643579 Oral vaccines  
Methods and vaccines for the production of antibodies to infectious organisms are described. Live recombinant adenovirus containing a foreign gene coding for an antigen produced by another...
5639594 Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis  
The present invention relates to novel linear and branched peptides specific for the diagnosis and prevention of non-A, non-B hepatitis (NANBH), as well as hepatitis C virus (HCV) infection. More...
5614384 Hepatitis B virus surface proteins with reduced host carbohydrate content  
In order to produce hepatitis B virus (HBV) surface proteins in the form of particles with substantially reduced entrapped carbohydrate content, DNA encoding the HBV surface proteins was expressed...
5607851 Process for purifying hepatitis a virus (HAV), and vaccine compositions containing hepatitis a virus  
A process is described for the purification of the hepatitis A virus, which allows one to obtain with good yields a pure product, in which organic material collected by centrifugation after lysis...
5582968 Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis  
The present invention relates to novel branched peptides specific for the diagnosis and prevention of non-A, non-B hepatitis (NANBH), as well as hepatitis C virus (HCV) infection. More...
Matches 101 - 150 out of 169 < 1 2 3 4 >